Home > Insider Trading > Filing (0001126234-14-000044)

Filing Details

Accession Number:: 0001126234-14-000044
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-01-15 20:58:25
Reporting Period:: 2014-01-13

Filing Date:: 2014-01-15
Accepted Time:: 2014-01-15 20:58:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1126234	Newlink Genetics Corp	(NLNK)	Pharmaceutical Preparations (2834)	421491350

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1512114	N. Nicholas Vahanian	C/O Newlink Genetics Corporation 2503 South Loop Dr., Suite 5100 Ames IA 50010	President, Chief Medical Offic	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2014-01-13	10,000	$26.00	80,480	No	4	S	Direct
Common Stock	Disposition	2014-01-14	16,336	$26.58	64,144	No	4	S	Direct
Common Stock	Acquisiton	2014-01-14	18,664	$2.10	82,808	No	4	M	Direct
Common Stock	Disposition	2014-01-14	18,664	$26.58	64,144	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2014-01-14	18,664	$0.00	18,664	$2.10

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
290,374	2008-06-01	2019-05-12	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	52,856	Indirect	By Spouse

Footnotes

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on 10/28/2013.
Includes 15,000 restricted stock units ("RSUs") previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in a series of four successive annual installments beginning on January 2, 2015, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.32 to $26.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote 3 to this Form 4.
Grant to the Reporting Person of a stock option under the Plan. The option vests over a five-year period, with 20% of such option vesting on the one-year anniversary of the vesting commencement date and the remaining 80% of such option vesting in equal monthly installments over the next 48 months, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the date of grant.